SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) saw some unusual options trading on Tuesday. Stock traders acquired 261,202 call options on the stock. This represents an increase of 522% compared to the average volume of 42,008 call options.

Wall Street Analyst Weigh In

SLS has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, October 15th. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SELLAS Life Sciences Group currently has a consensus rating of “Hold” and an average target price of $10.00.

Read Our Latest Analysis on SLS

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nykredit A S purchased a new position in SELLAS Life Sciences Group in the second quarter valued at about $27,000. GAMMA Investing LLC raised its stake in shares of SELLAS Life Sciences Group by 293.2% in the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock worth $27,000 after purchasing an additional 1,630 shares during the last quarter. Robinhood Markets Inc. purchased a new position in SELLAS Life Sciences Group during the 3rd quarter worth approximately $33,000. Allworth Financial LP raised its holdings in shares of SELLAS Life Sciences Group by 1,107.2% during the third quarter. Allworth Financial LP now owns 5,698 shares of the company’s stock worth $70,000 after purchasing an additional 5,226 shares during the last quarter. Finally, Sterling Capital Management LLC raised its stake in shares of SELLAS Life Sciences Group by 900.8% during the 3rd quarter. Sterling Capital Management LLC now owns 6,635 shares of the company’s stock valued at $82,000 after buying an additional 5,972 shares during the last quarter. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group News Summary

Investors following SLS have been watching these news items:

  • Positive Sentiment: SELLAS reported that its Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary endpoint in a specific group of patients with acute myeloid leukemia (AML). GPS was associated with a 41% lower risk of death and median overall survival of 24 months, versus 14.7 months with best available treatment (hazard ratio 0.59; p=0.035). The positive efficacy result is the main catalyst behind the stock’s initial surge. SELLAS REGAL trial results
  • Neutral Sentiment: Trading activity was unusually intense, including temporary volatility-related trading pauses and a large increase in call-option volume, reflecting heightened investor interest as well as elevated volatility.
  • Negative Sentiment: SELLAS announced a proposed $150 million underwritten public offering. Issuing shares could dilute existing shareholders and added selling pressure after the trial-driven rally. Proposed public offering

SELLAS Life Sciences Group Trading Down 6.3%

Shares of SLS opened at $17.95 on Thursday. The firm has a market capitalization of $3.66 billion, a P/E ratio of -89.75 and a beta of 2.73. The firm has a fifty day moving average price of $11.09 and a 200-day moving average price of $8.94. SELLAS Life Sciences Group has a 12-month low of $1.39 and a 12-month high of $24.89.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05).

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.

Featured Stories

Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.